1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Corneal Crosslinking Devices Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Corneal Crosslinking Devices by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Corneal Crosslinking Devices by Country/Region, 2018, 2022 & 2029
2.2 Corneal Crosslinking Devices Segment by Type
2.2.1 Epithelium-off Method
2.2.2 Epithelium-on Method
2.3 Corneal Crosslinking Devices Sales by Type
2.3.1 Global Corneal Crosslinking Devices Sales Market Share by Type (2018-2023)
2.3.2 Global Corneal Crosslinking Devices Revenue and Market Share by Type (2018-2023)
2.3.3 Global Corneal Crosslinking Devices Sale Price by Type (2018-2023)
2.4 Corneal Crosslinking Devices Segment by Application
2.4.1 Eye Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Corneal Crosslinking Devices Sales by Application
2.5.1 Global Corneal Crosslinking Devices Sale Market Share by Application (2018-2023)
2.5.2 Global Corneal Crosslinking Devices Revenue and Market Share by Application (2018-2023)
2.5.3 Global Corneal Crosslinking Devices Sale Price by Application (2018-2023)
3 Global Corneal Crosslinking Devices by Company
3.1 Global Corneal Crosslinking Devices Breakdown Data by Company
3.1.1 Global Corneal Crosslinking Devices Annual Sales by Company (2018-2023)
3.1.2 Global Corneal Crosslinking Devices Sales Market Share by Company (2018-2023)
3.2 Global Corneal Crosslinking Devices Annual Revenue by Company (2018-2023)
3.2.1 Global Corneal Crosslinking Devices Revenue by Company (2018-2023)
3.2.2 Global Corneal Crosslinking Devices Revenue Market Share by Company (2018-2023)
3.3 Global Corneal Crosslinking Devices Sale Price by Company
3.4 Key Manufacturers Corneal Crosslinking Devices Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Corneal Crosslinking Devices Product Location Distribution
3.4.2 Players Corneal Crosslinking Devices Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Corneal Crosslinking Devices by Geographic Region
4.1 World Historic Corneal Crosslinking Devices Market Size by Geographic Region (2018-2023)
4.1.1 Global Corneal Crosslinking Devices Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Corneal Crosslinking Devices Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Corneal Crosslinking Devices Market Size by Country/Region (2018-2023)
4.2.1 Global Corneal Crosslinking Devices Annual Sales by Country/Region (2018-2023)
4.2.2 Global Corneal Crosslinking Devices Annual Revenue by Country/Region (2018-2023)
4.3 Americas Corneal Crosslinking Devices Sales Growth
4.4 APAC Corneal Crosslinking Devices Sales Growth
4.5 Europe Corneal Crosslinking Devices Sales Growth
4.6 Middle East & Africa Corneal Crosslinking Devices Sales Growth
5 Americas
5.1 Americas Corneal Crosslinking Devices Sales by Country
5.1.1 Americas Corneal Crosslinking Devices Sales by Country (2018-2023)
5.1.2 Americas Corneal Crosslinking Devices Revenue by Country (2018-2023)
5.2 Americas Corneal Crosslinking Devices Sales by Type
5.3 Americas Corneal Crosslinking Devices Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Corneal Crosslinking Devices Sales by Region
6.1.1 APAC Corneal Crosslinking Devices Sales by Region (2018-2023)
6.1.2 APAC Corneal Crosslinking Devices Revenue by Region (2018-2023)
6.2 APAC Corneal Crosslinking Devices Sales by Type
6.3 APAC Corneal Crosslinking Devices Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Corneal Crosslinking Devices by Country
7.1.1 Europe Corneal Crosslinking Devices Sales by Country (2018-2023)
7.1.2 Europe Corneal Crosslinking Devices Revenue by Country (2018-2023)
7.2 Europe Corneal Crosslinking Devices Sales by Type
7.3 Europe Corneal Crosslinking Devices Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Corneal Crosslinking Devices by Country
8.1.1 Middle East & Africa Corneal Crosslinking Devices Sales by Country (2018-2023)
8.1.2 Middle East & Africa Corneal Crosslinking Devices Revenue by Country (2018-2023)
8.2 Middle East & Africa Corneal Crosslinking Devices Sales by Type
8.3 Middle East & Africa Corneal Crosslinking Devices Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Corneal Crosslinking Devices
10.3 Manufacturing Process Analysis of Corneal Crosslinking Devices
10.4 Industry Chain Structure of Corneal Crosslinking Devices
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Corneal Crosslinking Devices Distributors
11.3 Corneal Crosslinking Devices Customer
12 World Forecast Review for Corneal Crosslinking Devices by Geographic Region
12.1 Global Corneal Crosslinking Devices Market Size Forecast by Region
12.1.1 Global Corneal Crosslinking Devices Forecast by Region (2024-2029)
12.1.2 Global Corneal Crosslinking Devices Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Corneal Crosslinking Devices Forecast by Type
12.7 Global Corneal Crosslinking Devices Forecast by Application
13 Key Players Analysis
13.1 Glaukos Corporation
13.1.1 Glaukos Corporation Company Information
13.1.2 Glaukos Corporation Corneal Crosslinking Devices Product Portfolios and Specifications
13.1.3 Glaukos Corporation Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Glaukos Corporation Main Business Overview
13.1.5 Glaukos Corporation Latest Developments
13.2 EMAGine AG
13.2.1 EMAGine AG Company Information
13.2.2 EMAGine AG Corneal Crosslinking Devices Product Portfolios and Specifications
13.2.3 EMAGine AG Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 EMAGine AG Main Business Overview
13.2.5 EMAGine AG Latest Developments
13.3 Peschke GmbH
13.3.1 Peschke GmbH Company Information
13.3.2 Peschke GmbH Corneal Crosslinking Devices Product Portfolios and Specifications
13.3.3 Peschke GmbH Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Peschke GmbH Main Business Overview
13.3.5 Peschke GmbH Latest Developments
13.4 IROMED GROUP Srl
13.4.1 IROMED GROUP Srl Company Information
13.4.2 IROMED GROUP Srl Corneal Crosslinking Devices Product Portfolios and Specifications
13.4.3 IROMED GROUP Srl Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 IROMED GROUP Srl Main Business Overview
13.4.5 IROMED GROUP Srl Latest Developments
13.5 Ivis Technologies S.R.l.
13.5.1 Ivis Technologies S.R.l. Company Information
13.5.2 Ivis Technologies S.R.l. Corneal Crosslinking Devices Product Portfolios and Specifications
13.5.3 Ivis Technologies S.R.l. Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Ivis Technologies S.R.l. Main Business Overview
13.5.5 Ivis Technologies S.R.l. Latest Developments
13.6 AJL Ophthalmic S.A.
13.6.1 AJL Ophthalmic S.A. Company Information
13.6.2 AJL Ophthalmic S.A. Corneal Crosslinking Devices Product Portfolios and Specifications
13.6.3 AJL Ophthalmic S.A. Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 AJL Ophthalmic S.A. Main Business Overview
13.6.5 AJL Ophthalmic S.A. Latest Developments
13.7 Safilo Group
13.7.1 Safilo Group Company Information
13.7.2 Safilo Group Corneal Crosslinking Devices Product Portfolios and Specifications
13.7.3 Safilo Group Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Safilo Group Main Business Overview
13.7.5 Safilo Group Latest Developments
13.8 VitaBiotics
13.8.1 VitaBiotics Company Information
13.8.2 VitaBiotics Corneal Crosslinking Devices Product Portfolios and Specifications
13.8.3 VitaBiotics Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 VitaBiotics Main Business Overview
13.8.5 VitaBiotics Latest Developments
13.9 Amway
13.9.1 Amway Company Information
13.9.2 Amway Corneal Crosslinking Devices Product Portfolios and Specifications
13.9.3 Amway Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Amway Main Business Overview
13.9.5 Amway Latest Developments
13.10 Bausch Health
13.10.1 Bausch Health Company Information
13.10.2 Bausch Health Corneal Crosslinking Devices Product Portfolios and Specifications
13.10.3 Bausch Health Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Bausch Health Main Business Overview
13.10.5 Bausch Health Latest Developments
13.11 Essilor
13.11.1 Essilor Company Information
13.11.2 Essilor Corneal Crosslinking Devices Product Portfolios and Specifications
13.11.3 Essilor Corneal Crosslinking Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Essilor Main Business Overview
13.11.5 Essilor Latest Developments
14 Research Findings and Conclusion
| ※参考情報 角膜クロスリンキング（CXL）は、主に角膜の強度を向上させ、角膜変形症（例：円錐角膜）などの視覚的問題を治療するための医療技術です。この技術は、角膜を特定の方法で結合させることで、その構造を強化し、視力を改善することを目的としています。角膜クロスリンキングに用いるデバイスは、治療の成功を左右する重要な役割を果たします。 角膜クロスリンキング用デバイスの基本的な概念として、まず、通常はリボフラビンと呼ばれるビタミンB2の一種を用いて角膜に光を照射することが挙げられます。リボフラビンは、紫外線（UV）光によって活性化され、酸素と反応することで、角膜内のコラーゲン繊維を架橋形成します。これにより、角膜の強度や耐久性が向上し、変形を防ぐ効果があります。 このデバイスの特徴として、まず第一に、使いやすさと安全性が求められます。医療現場では迅速かつ正確に手技を行う必要があり、操作が簡単であることも重要です。また、患者の安全を最優先に考えるため、デバイスは高い安全基準をクリアしている必要があります。さらに、角膜の状態や治療の段階に応じて調整可能な機能も重要な特徴の一つです。 種類としては、主に2つのアプローチが存在します。一つは「通常型クロスリンキング」と呼ばれるもので、リボフラビンを点眼し、紫外線照射を行う一般的な方法です。もう一つは「トラフクロスリンキング」と呼ばれ、より重度の角膜変形症患者に対して用いられます。この方法では、角膜の深部まで浸透させるための工夫がなされています。 用途については、角膜クロスリンキングは特に円錐角膜の治療に用いられることが多いです。円錐角膜は、角膜が薄くなり、前方に突出してしまう疾患であり、これによって視力が著しく低下することがあります。この治療法は、進行を抑制し、場合によっては視力を改善することが実証されています。また、一部の研究では、屈折矯正手術の後の角膜安定化や、糖尿病性角膜病変の治療にも応用されている例があります。 関連技術としては、角膜クロスリンキングにはいくつかの併用治療法が考えられます。たとえば、レーザー治療と組み合わせることで、より一層の効果を得ることができるとされています。また、角膜を形成する細胞に対するエクソソーム研究も進行中で、その技術がクロスリンキングと連携する可能性もあります。さらに、バイオマテリアルを用いた新しい材料の開発が進められており、より効果的なデバイスが期待されています。 結論として、角膜クロスリンキング用デバイスは、眼科領域において非常に重要な役割を果たしています。患者の角膜を科学的に結合させることで、視力の改善や品質の向上が可能となります。今後の研究や技術革新により、さらに多くの適用可能性が広がることが期待されています。医学と技術の融合によって、より多くの患者に利益をもたらすことができるでしょう。これにより、角膜の健康が保たれ、視生活の質が改善されることが期待されます。 |
